This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. In the AWARD-1 trial, people gained an average of 0.2kg in weight with dulaglutide 0.75mg, In the AWARD-3 trial weight loss with dulaglutide was similar to metformin, In the AWARD -4 trial, weight loss with dulaglutide 1.5mg was 0.87kg, while dulaglutide 0.75mg was weight neutral at 26 weeks, In the AWARD-6 trial, average weight loss was 2.8kg with dulaglutide 1.5mg compared to 3.6kg with liraglutide. - Full-Length Features Furthermore, from a mean baseline body weight of 95 kg and a BMI of 33.5 kg/m 2, people treated with 0.5 mg semaglutide experienced a statistically significant and superior weight loss … Again, this is similar to other GLP-1 receptor agonists. All patients were initiated on once-weekly 0.75 mg dulaglutide for 4 weeks, and then the dose was escalated to the randomized dose. Dulaglutide works by mimicking the functions of natural incretin hormones in the body that help keep blood sugar levels under control, especially immediately following a meal. Patients (N=1842) with type 2 diabetes mellitus were recruited from 203 sites in 15 countries for the Assessment of Weekly Administration of LY2189265 in Diabetes-11 (AWARD-11) trial. Among patients with type 2 diabetes who had poor glycemic control with metformin therapy, weekly dulaglutide resulted in clinically relevant weight loss and glycated hemoglobin (HbA1c) reduction. Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. - Case Studies Serious events (8.3% vs 6.8% vs 6.2%) and death (0.5% vs 0.6% vs 0.7%) were rare. Enjoying our content? One of the ways dulaglutide works is by helping to make you feel full after a meal. Disclosure: Multiple authors declared affiliations with industry. Therefore patients who fail to achieve a reduction in HbA1c of at Subcutaneous semaglutide (Ozempic®), dulaglutide and liraglutide 1.2 mg (Victoza®) are not licensed for weight loss, nor approved within NCL for this indication. Among patients with type 2 diabetes who had poor glycemic control with metformin therapy, weekly dulaglutide resulted in clinically relevant weight loss and glycated hemoglobin (HbA1c) reduction. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Patients were randomly assigned in a 1:1:1 ratio to receive 1.5 (n=612), 3.0 (n=616), or 4.5 (n=614) mg weekly dulaglutide subcutaneous injection for a 2-week lead-in period and then treatment for 52 weeks followed by a 4-week safety assessment. Dulaglutide is injected under the skin once a week, preferably on the same day each week at the same time. “Now, with the 3.0 and 4.5 doses available, people with type 2 diabetes who use Trulicity can benefit from additional A1C and weight loss as … Dulaglutide 1.5 mg once weekly vs. liraglutide 1.8 mg once daily Metformin 26 Similar (–0.06 [–0.19 to 0.07],,0.0001 for noninferiority) Significantly less with dulaglutide than liraglutide (0.71 [0.17–1.26], 0.011) Nausea: 20 vs. 18% This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. However, it can be stimulated with pharmacological agents, such as Dulaglutide. Diabetes Obes Metab. Efficacy and safety were assessed. Liraglutide, first approved as a weight loss medicine also requires to be injected daily. These findings, from a randomized, double-blind, parallel-arm study, were published in … Registration is free. It is usually prescribed after oral medications for diabetes have not worked or have stopped working. Find out everything you need to know about weight loss drugs in our prescription weight loss pill guide. Compared with the low-dose group, patients receiving 4.5 mg were more likely to have less than 7% (odds ratio [OR], 2.2; 95% CI, 1.7-3.0; P <.001) or 6.5% or less (OR, 2.0; 95% CI, 1.5-2.6; P <.001) change of HbA1c at 36 weeks. Treatment options include Last updated on Sep 14, 2020. However, some people gained weight. In clinical studies, weight change was a secondary endpoint. They also stimulate the secretion of insulin in response to high blood glucose levels. Dulaglutide acts like GLP-1 and binds to GLP-1 receptors, stimulating insulin release from the pancreas, reducing the amount of glucose that the liver produces, and making you feel full by slowing gastric emptying. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. 2019;21(6):1340‐1348. In SUSTAIN 7, 0.06 kg of a total of 2.26 kg of the greater weight loss at EOT (week 40) observed with semaglutide 0.5 mg vs dulaglutide 0.75 mg and 0.08 kg of a total of 3.55 kg for semaglutide 1.0 mg vs dulaglutide 1.5 mg was mediated by nausea/vomiting from baseline to week 12 (both p<0.0001; figure 2A). 49% of people in the study administered dulaglutide did not gain weight compared with only 19% administered insulin glargine. However, weight loss in the insulin glargine group was not evident, and the improvement in NAFLD was not associated with weight loss from the results reported by Tang et al. here. “Our paper shows that liraglutide, administered for 3 months at the approved dose of 3 milligrams per day, was associated with an average weight … The most common side effects of Trulicity include nausea, diarrhea, vomiting, abdominal pain and decreased appetite, indigestion, and fatigue. Research has shown that many people lose, on average, two to six pounds while taking dulaglutide. Symptoms include excessive thirst, frequent urination, weight loss, fatigue, and an unusual odor to your urine. Data sources include IBM Watson Micromedex (updated 3 Mar 2021), Cerner Multum™ (updated 1 Mar 2021), ASHP (updated 3 Mar 2021) and others. These are not all the possible side effects of Trulicity. Select one or more newsletters to continue. Dulaglutide is an injectable medicine that is used to improve blood sugar control in adults over the age of 18 with type 2 diabetes. Please refer to the original article for a full list of disclosures. Trulicity can cause weight loss, although it is not a weight loss drug. doi:10.1111/dom.13658, Dar, S., Tahrani, A.A. and Piya, M.K. Published online January 4, 2021. Mean weight change from baseline ranged from +0.4 lb to -10.1 lb from 0.75 mg dose to 4.5 mg dose. Like other GLP-1 receptors agonists, Trulicity works by stimulating the body’s natural production of insulin It also inhibits the release of glucagon and slows digestion. What is Trulicity (Dulaglutide) and how does it work? You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. Both groups experienced significant weight loss: 3.61 kg for liraglutide compared with 2.90 kg for dulaglutide ( P = .011). In the AWARD-11 trail, the average weight loss after 36 weeks was 4.7kg (10.4 pounds) with dulaglutide 4.5mg; 4kg (8.8 pounds) with dulaglutide 3mg; and 3kg (6.8 pounds) with dulaglutide 1.5mg. Don’t miss out on today’s top content on Endocrinology Advisor. Randomization occurred after stratifying patients by low (<8.5%) or high (³8.5%) HbA1c. In the AWARD-6 trial, average weight loss was 2.8kg with dulaglutide 1.5mg compared to … Incretin hormones are gut peptides that are secreted from the stomach when food is eaten. Trulicity is not indicated for weight loss. Dulaglutide was associated with a greater weight loss (3.23kg on average) compared to insulin glargine in 588 patients also taking insulin lispro. Taken once a week by injection, this drug can mimic many of the effects of weight loss Tell your doctor if you have any side effects. may have been insufficient to observe the effects of liraglutide on liver fat. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Use in Pregnancy Pregnancy Category B3. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Please login or register first to view this content. The shorter duration of the study by Tang et al. If you wish to read unlimited content, please log in or register below. 10–12 Semaglutide (Novo Nordisk, Denmark) is a GLP-1RA All participants initiated once-weekly dulaglutide 0.75 mg for 4 weeks, followed by a stepwise dose escalation every 4 weeks to the randomized dose of 1.5 mg, 3 mg or 4.5 mg. Body weight was significantly decreased among the 3.0-mg (ETD, -0.9; 95% CI, -1.4 to -0.4 kg; P =.001) and 4.5-mg (ETD, -1.6; 95% CI, -2.1 to -1.1 kg; P <.001) groups compared with the 1.5-mg cohort at 36 weeks. About Dulaglutide (Trulicity) GLP 1 agonists include exenatide which requires twice-daily administration through a syringe. Thanks for visiting Endocrinology Advisor. If the FDA says yes, a major new weight loss drug may hit the market this year. Two incretin hormones are known as GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). We hope you’re enjoying the latest clinical news, full-length features, case studies, and more. Weight loss with dulaglutide 1.5 mg once weekly was similar to that seen with exenatide 10 microgram twice daily and less than that seen with liraglutide 1.8 mg daily. Dulaglutide shares 90% of the same structure as human GLP-1 but is man-made. Weight loss is a recognized outcome of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy and all currently available GLP‐1RAs (albiglutide, dulaglutide, exenatide, liraglutide and lixisenatide) promote weight loss in 11, 12 doi:10.1002/pdi.1978, FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes 09/2020 https://www.drugs.com/newdrugs/fda-approves-additional-doses-trulicity-dulaglutide-type-2-diabetes-5346.html. People more likely to lose weight include those with a higher starting weight and a longer duration of gastrointestinal side effects. Weight loss may be more important for some people, particularly those who do not already practice healthy eating and exercise habits. Specific studies have shown: Although overall treatment with GLP-1 receptor agonists is associated with weight loss, this varies among individuals, and 15 to 30% of people will gain weight. Trulicity (dulaglutide) is a recently FDA-approved medication for diabetics who have trouble controlling their appetites and losing weight. Research Design and MethodsForty-one obese women (aged 48 11 years and BMI 33.1 4.1 kg/m2) participated in a 35-week randomized, double-blind, Patients had a mean age of 57.1 (±10.0) years, and 48.8% were women. Trulicity also aids weight loss. Medically reviewed by Carmen Fookes, BPharm. Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). These findings, from a randomized, double-blind, parallel-arm study, were published in Diabetes Care. At 36 weeks, the least-square mean change of HbA1c was -1.54%, -1.64%, and -1.77% for the low-, intermediate-, and high-dose groups, respectively.